-- Days : -- HRS : -- MIN : -- SEC
Register Now →
Publication|Articles|December 10, 2025

Supplements and Featured Publications

  • Expert Consensus on Essential Characteristics of Oncology Value-Based Payment

Participating Faculty: Expert Consensus on Essential Characteristics of Oncology Value-Based Payment

Listen
0:00 / 0:00

Faculty

Michael Fazio

Head of Value-Based Care, Navista

Cardinal Health

Dublin, OH

Rhonda Henschel, MBA

Senior Vice President

Payer and Care Transformation

The US Oncology Network

McKesson

The Woodlands, TX

Aaron J. Lyss, MBA

Senior Director

Payment and Policy Innovation

OneOncology

Nashville, TN

Kiana Mehring, MBA, PPMC, LION

Vice President

Payer Strategy & Revenue Cycle Management

Florida Cancer Specialists, LLC

Fort Myers, FL

Shilpa Trivedi, MSC, MS, SSQB

Director

Value-Based Care

Oncology Consultants PA

Houston, TX

Lalan Wilfong, MD

Senior Vice President

Value-Based Care

Thyme Care

Nashville, TN

Mary L. Witkowski, MD, MBA

Lecturer

Department of Global Health and Social Medicine

Harvard Medical School

Boston, MA

Andrew T. Yue, PhD

Data Science Lead

Tuple Health

Washington, DC

Faculty Disclosures

These faculty have disclosed the following relevant commercial financial relationships or affiliations in the past 12 months.

Rhonda Henschel, MBA

EMPLOYMENT

The US Oncology Network

MEETING/CONFERENCE ATTENDANCE

Community Oncology Alliance Annual Meeting; Community Oncology Alliance Payer Exchange Summit; Association for Value-Based Cancer Care Summit

Aaron J. Lyss, MBA

CONSULTANCIES OR PAID ADVISORY BOARDS

Bristol Myers Squibb; Gilead Sciences, Inc

EMPLOYMENT

OneOncology

STOCK OWNERSHIP

OneOncology

Kiana Mehring, MBA, PPMC, LION

EMPLOYMENT

Florida Cancer Specialists, LLC

Lalan Wilfong, MD

EMPLOYMENT

Thyme Care

Michael Fazio; Shilpa Trivedi, MSC, MS, SSQB; Mary L. Witkowski, MD, MBA; and Andrew T. Yue, PhD, have no relevant commercial financial relationships or affiliations to disclose.

This supplement was developed based on the findings of a Johnson & Johnson–
sponsored roundtable event. Mr Fazio, Mr Lyss, Ms Mehring, Ms Trivedi, Dr Wilfong, Dr Witkowski, and Dr Yue were compensated for their time and participation in the roundtable discussions but did not receive honoraria for their contributions to the development, writing, or preparation of this article.

Articles in this issue

Related to this article

Kenneth Komorny, PharmD, BCPS | Image: Moffitt Cancer Center
At a Stakeholder Interchange convened by The American Journal of Managed Care® in Tampa, Florida, an academic-community mix of hematologist-oncologists and pharmacists debated prior authorization, site-of-care payment disparities, and how aggressively to push bispecific antibody regimens to community practices treating patients with relapsed/refractory multiple myeloma.
Andrew D. Zelenetz, MD, PhD, is the chair of the NCCN B-cell Lymphomas panel.  | Image: LinkedIn
The National Comprehensive Cancer Network update on mantle cell lymphoma puts covalent BTK inhibitors, MRD testing, and TP53 sequencing at the center of frontline care, while adding pirtobrutinib and a pair of CAR T-cell therapies for disease that progresses on a BTK inhibitor.